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Background: Mesenchymal stromal/stem cells derived from human umbilical cord (UC-MSCs) uniquely combine
properties of embryonic and postnatal MSCs and may be the most acceptable, safe, and effective source for
allogeneic cell therapy e.g. for therapeutic angiogenesis. In this report we describe pro-angiogenic properties of
UC-MSCs as manifested in vitro.
Methods: UC-MSCs were isolated from human Wharton’s jelly by enzymatic digestion. Presence of soluble forms
of VEGF-A in UC-MSC-conditioned media was measured by ELISA. Effects of the conditioned media on human
umbilical vein-derived endothelial EA.hy926 cells proliferation were measured by MTT-assay; changes in cell
motility and directed migration were assessed by scratch wound healing and transwell chamber migration assays.
Angiogenesis was modeled in vitro as tube formation on basement membrane matrix. Progressive differentiation
of MSCs to endothelioid progeny was assessed by CD31 immunostaining.
Results: Although no detectable quantities of soluble VEGF-A were produced by UC-MSCs, the culture medium,
conditioned by the UC-MSCs, effectively stimulated proliferation, motility, and directed migration of EA.hy926
cells. In 2D culture, UC-MSCs were able to acquire CD31+ endothelial cell-like phenotype when stimulated by
EA.hy926-conditioned media supplemented with VEGF-A165. UC-MSCs were capable of forming unstable 2D
tubular networks either by themselves or in combinations with EA.hy926 cells. Active spontaneous sprouting from cell
clusters, resulting from disassembling of such networks, was observed only in the mixed cultures, not in pure UC-MSC
cultures. In 3D mode of sprouting experimentation, structural support of newly formed capillary-like structures
was provided by UC-MSCs that acquired the CD31+ phenotype in the absence of exogenous VEGF-A.
Conclusion: These data suggest that a VEGF-A-independent paracrine mechanism and at least partially VEGF-A-
independent differentiation mechanism are involved in the pro-angiogenic activity of UC-MSCs.
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The concept of therapeutic angiogenesis stems from un-
derstanding the importance of adequate microvascular
supply for growth and regeneration of affected tissues; it
refers to actions performed to facilitate revascularization
of ischemic tissues. As long as the direct delivery of ex-
ogenous cytokines and growth factors is ineffective, pri-
marily because of their rapid elimination in vivo [1],
expert opinions agree that the most promising approach
for therapeutic angiogenesis is represented by stem cell
therapy using multipotent mesenchymal stromal/stem
cells (MSCs) because it comprises simultaneous activa-
tion of multiple mechanisms (paracrine, replacement,
trophic, immunomodulatory) to provide support on dif-
ferent stages of formation and maturation of blood ves-
sels [2–4]. Most of the research in this field is performed
on bone marrow-derived MSCs (which represent a ‘gold
standard’) or adipose tissue-derived MSCs; both lineages
have certain angiogenic potential and implement it in a
similar manner [2, 5]. The field of therapeutic angiogen-
esis is currently expanded by using MSCs from other
sources, importantly from the umbilical cord and pla-
centa. Perinatal stem cells share characteristics with both
embryonic and adult stem cells because they may exhibit
pluripotency as well as multipotent tissue maintenance,
thus representing a bridge between embryonic and adult
stem cells [6]. Umbilical cord-derived MSCs (UC-MSCs)
have distinct biological properties: they are highly prolif-
erative and enriched in transcriptionally active genes re-
lated to liver or cardiovascular system development and
function. Besides, UC-MSCs exhibit superior grades of
plasticity and immunomodulatory activity, lack tumori-
genicity, and are considered the best resource for allo-
geneic transplantation [7–10].
Although therapeutic efficacy of UC-MSC transplant-
ation to ischemic tissue is demonstrated in vivo [11], the
understanding of how these cells implement their pro-
angiogenic potential is far from complete, and there is a
certain controversy among reports on this subject. The
inner space of umbilical cord, net of large vessels, is oc-
cupied by special connective tissue, the Wharton jelly,
which is very loose and rich in gel-like ground sub-
stance. Complete absence of microcirculatory vessels
from Wharton jelly may indicate some anti-angiogenic
properties of this microenvironment. The assumption is
partially supported by recent in vitro studies. For in-
stance, Kuchroo et al. [12] show that UC-MSCs do not
produce detectable amounts of soluble vascular endothe-
lial growth factor (VEGF)-A protein (strictly speaking,
they probably do because the corresponding gene is ac-
tively transcribed, but apparently this secreted VEGF-A
is saturated by soluble VEGF-A-specific receptors that
are also secreted by UC-MSC and act as a buffer); at the
same time, the authors observe certain stimulatinginfluences of UC-MSCs on umbilical vein-derived endo-
thelial cells in vitro and suggest the existence of some
alternative, VEGF-independent mechanism for this
stimulation. A comparative study by Amable et al. [13]
describe a shifted balance of pro-angiogenic and anti-
angiogenic factors in UC-MSC secretome, as compared
with MSCs from other conventional sources. Ways in
which UC-MSCs interact with endothelial cells and their
own responses to inducers of endothelial differentiation
represent an open issue. In the current study, the pro-
angiogenic activity of human UC-MSCs is challenged
in vitro by modeling of angiogenesis using 2D and 3D
artificial matrices. Several specifically addressed prob-
lems include the importance of VEGF-A, modes of UC-
MSC cooperation with umbilical vein-derived endothe-
lial EA.hy926 cells, and UC-MSC ability to acquire
CD31+ phenotypes under various stimulations.
Methods
Cell cultures
The study involving human material was approved by
the Ethics Committee at the Research Center for Obstet-
rics, Gynecology and Perinatology. Written informed
consent was obtained from all participants prior to the
study.
MSCs were isolated from human umbilical cords (n = 5).
The material was rinsed in phosphate-buffered saline (PBS)
with 1 mg/ml cefazolin (Sintez, Kurgan, Russia) and cut
into 3–4 cm pieces. After removal of blood vessels and am-
nion, the Wharton jelly was chopped into smaller frag-
ments with scissors. The fragments were incubated with
200 U/ml collagenase type I (PanEco, Moscow, Russia) and
40 U/ml dispase (Invitrogen, Waltham, MA, USA) for
60 minutes at 37 °C. After the addition of fetal bovine
serum (FBS; GE Healthcare, Pittsburg, PA, USA), the
digested mixture was centrifuged at 1000 × g for 10 minutes
at room temperature. Finally, the digested pieces were
washed with serum-free Dulbecco’s modified Eagle’s
medium (DMEM; PanEco) and cultured in growth
medium (DMEM/F12 supplemented with 10 % FBS and
1 % penicillin–streptomycin (PanEco)) in a humidified in-
cubator at 37 °C under a 5 % CO2 atmosphere.
UC-MSCs were characterized according to the min-
imal criteria to define human MSCs as proposed by the
Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy [14]. For
immunophenotype analysis, cells were labeled for 30 mi-
nutes at room temperature using the BD Stemflow™
hMSC Analysis Kit (BD Biosciences, Pharmingen, San
Diego, CA, USA). After being fixed with 4 % paraformal-
dehyde (SERVA Electrophoresis, Heidelberg, Germany),
the cells were analyzed on a FACScalibur using CellQuest
software (BD Biosciences). The StemPro® Adipogenesis
Differentiation Kit, the StemPro® Osteogenesis
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Differentiation Kit (Gibco, Life Technologies, Carlsbad,
CA, USA) were used to demonstrate the differentiation
capacity of UC-MSCs in accordance with the manufac-
turer’s instructions.
Human endothelial EA.hy926 cells were derived from the
American Type Culture Collection (Manassas, VA, USA).
Established in 1983 by fusing primary human umbilical vein
endothelial cells (HUVEC) with a thioguanine-resistant
clone of the human lung adenocarcinoma cell line A549/8,
EA.hy926 cells represent a widely-used endothelial cell line
expressing endothelin-1, Weibel-Palade bodies, prostacyc-
lin, factor VIII-related antigen, and endothelial adhesion
molecules ICAM-1 and VCAM-1 [15]. This line was
chosen for its highly specific functions that are characteris-
tic of the human vascular endothelium combined with ad-
vantages of immortality, stability through passage number,
and high reproducibility of the properties [16, 17].
Immunofluorescence
Cells were fixed with 4 % paraformaldehyde (SERVA
Electrophoresis) for 10 minutes at room temperature.
After two washes with PBS, the cells were blocked for
5 minutes with Protein Block (Abcam, Cambridge, MA,
USA) at room temperature and then incubated over-
night at 4 °C with antibodies against CD31 (ab24590;
Abcam). After washing with PBS, the cells were incu-
bated with fluorescein isothiocyanate (FITC)-conjugated
antimouse IgG (ab6810; Abcam) for 1 hour in the dark.
Cell nuclei were stained with 4′,6-diamidino-2-phenylin-
dole (DAPI; Sigma-Aldrich, St. Louis, MO, USA). The cells
were observed under the Leica DM 4000 B fluorescent
microscope (Leica Microsystems, Heidelberg, Germany).
Preparation of conditioned media
At 100 % confluence, the cells (UC-MSCs or EA.hy926)
were washed with serum-free DMEM, and the media
were replaced with fresh growth media. After 24, 48, or
72 hours, the media were collected and centrifuged at
2800 × g for 5 minutes, filtered through a 0.22 μm filter
(GE Osmonics Labstore, Minnetonka, MN, USA), and
were then stored at –70 °C until VEGF-A quantification.
The media conditioned by UC-MSCs or EA.hy926 cells
for 72 hours were used in subsequent experiments.
VEGF-A quantification
Media conditioned by EA.hy926 cells or UC-MSCs were
collected after 24, 48, or 72 hours. VEGF-А-121 and
VEGF-A-165 were quantified using a commercial enzyme-
linked immunosorbent assay kit (#8784; Vector-Best,
Novosibirsk, Russia) in accordance with the instructions
of the manufacturer. Data analysis was performed using
the online application (http://elisaanalysis.com/app).Endothelial cell proliferation assay
EA.hy926 cells were seeded in a 96-well plate (3 × 103 cells
in 200 μl of growth media per well). After 1, 2, or 3 days
the media were replaced with UC-MSC-conditioned
media, UC-MSC-conditioned media supplemented with
200 ng/ml anti-VEGF antibody (ab9570; Abcam), or
fresh growth media (control wells). At day 4 the cell
proliferation was measured by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
MTT (Sigma-Aldrich) stock solution was added to
each well (to a final MTT concentration of 1.5 mg/ml).
The plate was returned to a cell culture incubator for
2 hours. When the purple precipitate was clearly visible
under the microscope, 100 μl of dimethyl sulfoxide
(DMSO; Sigma-Aldrich) were added. After 15 minutes,
the absorbance in each well was measured at 570 nm in a
Multiskan GO microplate spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA). The reference
wavelength was 650 nm.
Endothelial cell transwell migration assay
The migration of EA.hy926 cells to UC-MSC-released
chemoattractants was measured by transwell chamber
migration assay. UC-MSCs were seeded in a 24-well
plate (105 cells in 600 μl of growth media per well).
One-half of the wells with the cells contained anti-VEGF
antibody (ab9570; Abcam) in 200 ng/ml final concentra-
tion. The same volume of growth media without cells
was added to control wells. After 24 hours, inserts with
a polycarbonate membrane (pore size of 8 μm) (#35224;
SPL Life Sciences, Pochun, South Korea) were installed
in the plate. EA.hy926 cells were seeded in the upper
chambers (105 cells in 250 μl of growth media). After 24,
48, or 72 hours, nonmigrating cells in the upper cham-
ber were attentively removed with cotton swabs, and
cells on the lower surface of the membrane were fixed
with 4 % paraformaldehyde (SERVA Electrophoresis)
and stained with DAPI (Sigma-Aldrich). The total num-
bers of migrated cells were then counted in eight ran-
domly selected fields for each insert (magnification × 100)
using LAS AF v.3.1.0 build 8587 (Leica Microsystems).
Endothelial cell scratch healing assay
EA.hy926 cells were seeded in a 96-well plate (3 × 104 cells
in 100 μl of growth media per well). After 24 hours, each
confluent cell monolayer was scratched with a Wound-
Maker™ tool (Essen Bioscience, Ann Arbor, MI, USA),
which created 96 homogeneous scratch wounds without
cell irritation. After washing with PBS, 100 μl of fresh
growth media, UC-MSC-conditioned media, or UC-MSC-
conditioned media supplemented with anti-VEGF anti-
body (ab9570; Abcam) in 200 ng/ml final concentration
were added to the wells. A 36-hour time-lapse movie was
created by IncuCyte ZOOM® Live-Cell Imaging Platform
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using an automated Cell Migration software module
(Essen BioScience).
In vitro tube formation assay
In this experiment we used BD Matrigel™ Basement
Membrane Matrix Phenol Red Free (#356237; BD Bio-
sciences). This matrix is highly enriched in laminin-1,
collagen IV, heparan sulfate, proteoglycan, entactin/nido-
gen, and various growth factors. Although it does not
contain all of the signature components of an endothe-
lial basement membrane, Matrigel promotes tube forma-
tion in vitro for all endothelial cells tested to date [18].
Prior to the experiment, UC-MSCs were labeled with
PKH26 (yellow–orange fluorescent dye) and EA.hy926
cells were labeled with PKH67 (green fluorescent dye)
(Sigma-Aldrich) according to the manufacturer’s instruc-
tions. A total of 150 μl of chilled Matrigel was added to
a 48-well plate and incubated at 37 °C for 30 minutes.
UC-MSCs, or EA.hy926 cells, or 1:1 mixed UC-MSC-
EA.hy926 cells (total 35 × 103 cells per well) were
suspended in 500 μl of growth media and were added to
the solidified Matrigel. Additionally, EA.hy926 cells sus-
pended in 500 μl of UC-MSC-conditioned media or UC-
MSC-conditioned media supplemented with 200 ng/ml of
anti-VEGF antibody (ab9570; Abcam) were used. After in-
cubation on Matrigel at 37 °C in a 5 % CO2 chamber, mor-
phological changes were observed under an Axiovert 40
CFL inverted microscope (Carl Zeiss, Jena, Germany).
Six representative fields for each well were photographed.
Images were analyzed using AxioVs40 4.8.2.0 (Zeiss,
Oberkochen, Germany) to determine the length of the tubes
and the number of branch points (magnification × 50).
Endothelial differentiation of UC-MSCs in monolayer
After UC-MSCs formed the confluent monolayer, the
growth media were replaced with the induction media.
Three endothelial induction media were used for UC-
MSC culture: EA.hy926-conditioned media mixed 1:1
with growth media; EA.hy926-conditioned media mixed
1:1 with growth media supplemented with VEGF-A-165
(#583702; BioLegend, San Diego, CA, USA), 50 ng/ml;
and growth media supplemented with VEGF-A-165.
Contents of FCS in the control and differentiation
media were reduced to 5 % to avoid excessive cell
growth. The media were replaced twice a week. At day
21, UC-MSCs were fixed with 4 % paraformaldehyde
(SERVA Electrophoresis) and stained with CD31 anti-
bodies as already described.
Endothelial differentiation of UC-MSCs in Matrigel
Whole mount immunostaining of the 3D structure,
formed by the cells in Matrigel, proved impossible due to
nonspecific absorption of the antibodies by the matrix.For this reason, the analysis was performed on cryosec-
tions of secondary sprouting networks. Structures formed
in Matrigel were embedded in Tissue-Tek® OCT Com-
pound (Sakura Finetek, Torrance, CA, USA) and cut into
5–7 μm sections using a cryostat. The sections were
stained with CD31 antibodies as already described.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Student’s t test was used for pairwise comparisons
between groups of normally distributed values, whereas
the Mann–Whitney test was applied for distributions
differing from normal. Multiple comparisons were done
by either one-way analysis of variance (ANOVA) or
ANOVA on ranks (for the cases of unconfirmed normal-
ity); p <0.05 was considered statistically significant.
Results
Characterization of cell cultures
The cells isolated from Wharton jelly of the human um-
bilical cord were plastic adherent with a spindle-shaped,
fibroblast-like morphology (Fig. 1b). Flow cytometry
analysis showed that these cells were positive for the
MSC markers CD105, CD73, and CD90 and were nega-
tive for CD11b, CD19, CD45, CD34, and HLA-DR
(Fig. 1a).
UC-MSCs demonstrated multipotent differentiation
potential. Sudan III staining of neutral lipid vacuoles
showed that UC-MSCs could differentiate into adipo-
cytes. Alizarin Red S staining of calcium compound
crystals showed that UC-MSCs could differentiate into
osteoblasts. Positive staining of mucopolysaccharides by
Alcian blue indicated that UC-MSCs could differentiate
into chondrocytes (Fig. 1b).
EA.hy926 cells formed a monolayer of closely apposed
small polygonal cells. EA.hy926 cells were found to be
positive for CD31 as endothelial marker (Fig. 1c).
VEGF-A-121 and VEGF-A-165 quantification in the
conditioned media
Within 3 days, the concentration of soluble forms of
VEGF-A (VEGF-A-121 and VEGF-A-165) in EA.hy926-
conditioned media gradually increased from 57.3 ± 7.7 pg/
ml to 229.0 ± 24.9 pg/ml, whereas in UC-MSC-conditioned
media the contents of VEGF-A did not change, remaining
at the level of the growth medium (Fig. 1d).
The influence of UC-MSC-conditioned media on
endothelial cell proliferation
Results of the MTT assay indicated that EA.hy926 cells
incubated in UC-MSC-conditioned media had a signifi-
cant increase in cell viability after a 24-hour incubation
when compared with cells incubated with growth media
alone (p < 0.05). Consequently, the difference between the
Fig. 1 Cell culture characterization. a Human UC-MSC immunophenotype, positive for CD73, CD90, and CD105 and negative for CD45, CD34,
CD11b, CD19, and HLA-DR. b Multilineage differentiation of UC-MSCs. Differentiation into adipocytes was revealed by Sudan III staining for
intracellular accumulated lipids. Differentiation into osteocytes was revealed by Alizarin Red S staining for calcium mineralization. Chondrogenic
differentiation was revealed by Alcian blue staining for mucopolysaccharides. Scale bar 100 μm. c Positive staining of EA.hy926 cells for CD31 as
endothelial marker. Scale bar 100 μm. d Concentration of soluble forms of VEGF-A (VEGF-A-121 and VEGF-A-165) in the EA.hy926-conditioned
media and the UC-MSC-conditioned media. Values are expressed as average ± SD of three replicates. *p <0.05. h hours, UC-MSC umbilical
cord-derived mesenchymal stromal/stem cell, VEGF vascular endothelial growth factor
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in almost 1.6-fold excess absorption in wells with UC-
MSC-conditioned media compared with growth media.
The addition of the VEGF-neutralizing antibody to the
UC-MSC-conditioned media did not significantly attenu-
ate the EA.hy926 cell proliferation as compared with the
UC-MSC-conditioned media treatment (p < 0.05)
(Fig. 2a).
The influence of UC-MSC-conditioned media on endothelial
cell migration
Endothelial cell migration was evaluated using a trans-
well chamber migration assay. EA.hy926 cells migrated
from the upper chamber to the lower surface of mem-
brane through 8 μm pores when the lower chamber con-
tained only the growth culture medium. When the lower
chamber was seeded with UC-MSCs, the efficacy of
EA.hy926 cell-directed migration increased significantlyat all time points (p <0.05). The addition of the VEGF-
neutralizing antibody to the lower chambers seeded with
UC-MSCs did not significantly attenuate the EA.hy926
cell migration as compared with UC-MSC-conditioned
media treatment (p <0.05) (Fig. 2b).
Additionally we used a scratch wound healing assay of
tissue-culture cell monolayers to measure the influence
of UC-MSC-conditioned media on endothelial cell
EA.hy926 migration. UC-MSC-conditioned media stim-
ulated the motility of endothelial cells during the wound
recovery; the difference became significant at 8 hours
after scratching. For example, at 18 hours after scratch-
ing, wound confluence in the control wells was 52.68 ±
5.80 % while in the wells with UC-MSC-conditioned
media this index reached 89.74 ± 5.63 %, and in the wells
with UC-MSC-conditioned media supplemented with
the VEGF-neutralizing antibody it reached 90.04 ±
5.26 %. The dynamics of wound confluence, illustrated
Fig. 2 Effects of UC-MSC-conditioned media on proliferation, directed migration, and motility of EA.hy926 cells. a Effects of UC-MSC-conditioned
media on proliferation of EA.hy926 cells was determined by MTT assay. Cells were treated with UC-MSC-conditioned media or UC-MSC-conditioned
media supplemented with anti-VEGF antibody for 1, 2, or 3 days. Control cells were treated with growth media for 3 days. Values are
expressed as average ± SD of three replicates. *p <0.05. b Migration of EA.hy926 cells to UC-MSC-released chemoattractants was measured by
transwell chamber migration assay. UC-MSCs were seeded in the lower part of transwell plates, while EA.hy926 cells were placed in the upper
chambers. (Upper) Representative images of EA.hy926 cells, which migrated to the other side of the membrane and were stained with DAPI.
Scale bar 200 μm. (Lower) Quantification of transwell chamber migration assay. Values are expressed as average ± SD of three replicates. *p <0.05.
c Effects of UC-MSC-conditioned media on motility of EA.hy926 cells was analyzed using wound healing assays. (Upper) Representative images of an
in vitro scratch wound healing assay in EA.hy926 cells in the presence of UC-MSC-conditioned media or UC-MSC-conditioned media supplemented
with anti-VEGF antibody, vs. growth media. Scale bar 200 μm. (Lower) Quantification of in vitro wound healing. Values are expressed as average ± SD of
three replicates. There was a significant increase in the wound confluence exposed to UC-MSC-conditioned media or UC-MSC-conditioned
media supplemented with anti-VEGF antibody compared with growth media at 8 hours after scratching. h hours, UC-MSC umbilical cord-derived
mesenchymal stromal/stem cell, VEGF vascular endothelial growth factor
Arutyunyan et al. Stem Cell Research & Therapy  (2016) 7:46 Page 6 of 13with representative images from the time-lapse record-
ing, is given in Fig. 2c.
Tube formation assay
The angiogenic capability of various cell types was assessed
using an in vitro capillary-like structure (tube) formation
assay on basement membrane matrix. As shown in Fig. 3a,
both UC-MSCs and endothelial EA.hy926 cells were ableto form the networks on Matrigel, but the parameters of
the networks were different. UC-MSCs and UC-MSCs
mixed 1:1 with EA.hy926 cells already began sprouting
1 hour after cell seeding. These networks were unstable
and began to disintegrate 3 hours later, just as EA.hy926
cells started sprouting. Additionally there was a difference
between the network structures: EA.hy926 cells formed fine
meshes with a greater number of branch points and shorter
Fig. 3 (See legend on next page.)
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Fig. 3 Matrigel tube formation assay. a UC-MSCs, or EA.hy926 cells, or 1:1 mixed UC-MSC-EA.hy926 cells in the presence of growth media, or
EA.hy926 cells in the presence of UC-MSC-conditioned media or UC-MSC-conditioned media supplemented with anti-VEGF antibody (total 35 ×
103 cells per well) were cultured in 48-well plates coated with Matrigel. (Right) Representative images of morphological changes of networks. Scale
bar 100 μm. (Left) Quantification of lengths of the tubes and numbers of branch points. Values are expressed as average ± SD. b PKH26-labeled UC-MSCs
(red) became the basis of a mixed culture network, while PKH67-labeled EA.hy926 cells (green) were only associated with it. Scale bar 100 μm. c Cluster
formation. (Left) Representative images of tight clusters formed in Matrigel by UC-MSCs, or EA.hy926 cells, or mixed UC-MSC-EA.hy926 cells 24 hours after
seeding. Macrophotograph of the 48-well plate. (Right) Quantification of numbers of clusters. Values are expressed as average ± SD of
three replicates. *p <0.05. h hours, UC-MSC umbilical cord-derived mesenchymal stromal/stem cell, VEGF vascular endothelial growth factor
(Color figure online)
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mix formed coarse meshes with fewer branch points and
longer tubes. The addition of UC-MSC-conditioned media
(regardless of the presence of the VEGF-neutralizing anti-
body) to the wells with EA.hy926 cells did not significantly
alter the parameters of the networks, but contributed to
their formation 1 hour earlier (Fig. 3a).
Surprisingly, we found that PKH26-labeled UC-MSCs
became the basis of a mixed culture network, while
PKH67-labeled EA.hy926 cells were only associated with
it (Fig. 3b).
In all groups, the networks were unstable and disinte-
grated into tight clusters for 24 hours. These clusters
were not stationary structures. In a few days, they were
capable of limited movement and fusion. The movement
of cell clusters stopped in about 5–7 days, and the num-
ber of clusters was different between the groups: 430.0 ±
21.2 per well for EA.hy926 cells, 137.1 ± 9.2 per well for
UC-MSC-EA.hy926 cell mix, and 93.0 ± 9.2 for UC-
MSCs (Fig. 3c).
Further, we observed that the clusters formed by the
EA.hy926 cells and UC-MSC-EA.hy926 cell mix, but
not by UC-MSCs alone, became centers of secondary
sprouting. Sprouting cells had a typical elongated
shape. Gradually, the isolated sprouting centers joined
into a single, very stable (follow-up of more than
30 days) 3D network with a plurality of branch points,
often dichotomic (Fig. 4a). Moreover, in this mixed cul-
ture network only PKH26-labeled UC-MSCs formed
sprouts while PKH67-labeled EA.hy926 cells stayed in
the centers of the clusters (Fig. 4b).
Endothelial differentiation of UC-MSCs in monolayer
UC-MSCs cultured in complete fresh growth medium
exhibited both the shape and the wave-like arrangement
of the MSCs in the monolayer; the cell growth was
restricted by mutual contact inhibition, and neither of
them differentiated to the CD31+ phenotype.
When cultured in EA.hy926-conditioned medium,
the cells retained the same characteristics but grew to
higher densities. When cultured in EA.hy926-condi-
tioned medium supplemented with VEGF-A-165, they
formed distinct tubular structures (three to five per35 mm dish), assembled from several dozens of narrow
stretched cells with elongated nuclei, positively stained
with CD31 antibody.
Finally, using VEGF-A-165 as a single growth supple-
ment (except for the serum), added to complete fresh
medium, led to a mosaic loss of contact inhibition. The
cells started to grow in multiple layers, but formed no
tubular structures and stayed CD31– (Fig. 5a).
Endothelial differentiation of UC-MSCs in Matrigel
Immunostaining of cryosections showed that, upon
coculturing with EA.hy926 in Matrigel, the UC-MSCs
started to express CD31 spontaneously, without add-
itional VEGF-A-165 supplement (Fig. 5b).
Discussion
Weak secretion of VEGF-A by UC-MSCs derived from
Wharton jelly may be related to the unusual structure of
loose connective tissue forming Wharton jelly, and, in
particular, the lack of blood capillaries in it. Although
early events of hematopoiesis and capillary formation in
this tissue are described in detail, by 7–9 weeks of devel-
opment the hematopoiesis in Wharton jelly ceases, and
the capillaries undergo regression [19]. It is plausible
that these changes, as well as subsequent maintenance
of the anti-angiogenic environment, are accompanied, or
mediated, by low concentrations of soluble VEGF-A in
the intercellular spaces. According to some authors, the
Wharton jelly-derived UC-MSCs are able to secrete sol-
uble forms of VEGF-A [20]; however, the majority of
the reports (including this one) mention the almost
complete absence of VEGF-A protein from the UC-
MSC-conditioned culture medium as a specific feature
reflecting VEGF-A deficiency of UC-MSC secretome.
Typical levels of VEGF-A secretion reported for UC-
MSCs are 102 less than for adipose tissue-derived MSCs
and 103 less than for bone marrow-derived MSCs, despite
detectable levels of transcription of the corresponding
gene [12, 13]. Nevertheless, UC-MSCs can effectively
accelerate migration and promote tube formation from
endothelial cells in vitro—the effect is mediated by the
UC-MSC-conditioned media; that is, by in vitro modeling
of in vivo paracrine mechanisms [12].
Fig. 4 Secondary sprouting in Matrigel. a Clusters formed in Matrigel by the EA.hy926 cells and UC-MSC-EA.hy926 cell mix, but not by UC-MSCs
alone, became centers of secondary sprouting. Gradually, the isolated sprouting centers joined into a single, very stable 3D network. Scale bar
100 μm. b In a mixed culture network only PKH26-labeled UC-MSCs (red) formed sprouts while PKH67-labeled EA.hy926 cells (green) stayed in the
centers of the clusters. Scale bar 100 μm. UC-MSC umbilical cord-derived mesenchymal stromal/stem cell (Color figure online)
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via some VEGF-A-independent mechanism. Why should
this matter? The problem is that intermediate results
of clinical trials using VEGF-A-121 or VEGF-A-165
(as active exogenous proteins or in the form of genetic
constructs) have been qualified as rather contradictory:
the effects sometimes deviate from those expected
[1, 21]. This may be explained by duality that originates
from the level of VEGF-A binding to its receptor, vascu-
lar endothelial growth factor receptor (VEGFR). By
acting via VEGFR2, VEGF-A increases survival and pro-
liferation of endothelial cells, as well as recruitment of
other progenitors to the site of injury, thus supporting
formation and maturation of new blood vessels; incontrast, the VEGFR1-mediated action of VEGF-A is
anti-angiogenic [1]. In some circumstances, excessive in-
flux of VEGF-A (either exogenous for cells in vitro, or
endogenous for ischemia models in vivo) may dysregu-
late intrinsic VEGFR balance of target cells and switch
them to VEGFR1 expression or may upregulate soluble
VEGFR1 expression that can operate as a negative feed-
back system, thereby undermining the entire positive ef-
fect of the treatment [22–24]. Moreover, the qualitative
and quantitative balance of VEGFR1 and VEGFR2 pro-
teins may vary in human populations, further complicat-
ing the proper choice of treatment for some cases [23].
Considering this, any VEGF-A-based pro-angiogenic
therapy may prove to be more reliable and lead to more
Fig. 5 Endothelial differentiation of UC-MSCs. a Endothelial differentiation of UC-MSCs in monolayer. Three endothelial induction media were
used for UC-MSC culture: EA.hy926-conditioned media mixed 1:1 with growth media; EA.hy926-conditioned media mixed 1:1 with growth
media supplemented with VEGF-A-165 (50 ng/ml); and growth media supplemented with VEGF-A-165. Only EA.hy926-conditioned media
supplemented with VEGF-A-165 led to the appearance of CD31+ cells in the culture. Cell nuclei were stained with DAPI. Scale bar 100 μm.
b Endothelial differentiation of UC-MSCs in Matrigel. Cryosections of secondary sprouts promoted by PKH26-labeled UC-MSCs (red). Immunostaining of
sections showed that, upon coculturing with EA.hy926 in Matrigel, the UC-MSCs started to express CD31 (green). Cell nuclei were stained with DAPI.
Scale bar 100 μm. VEGF vascular endothelial growth factor (Color figure online)
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VEGF-A-independent line of intervention (e.g., using
UC-MSCs).
Published evidence for the stimulating influence of
MSCs on endothelial cell proliferation is rather contro-
versial because of the variety of sources and methods of
obtaining the cells [2]. For example, it is shown that
bone marrow-derived MSCs (including cells cultured
under hypoxic conditions) have no effect on EA.hy926
cell growth [25]. In our experiments, the UC-MSC-
conditioned media stimulated proliferation of EA.hy926
cells; this is consistent with results reported by Choi
et al. [26] for a different endothelial line (HUVEC). The
absence of VEGF-A from UC-MSC-conditioned media
suggests that the endothelial cells respond to a different
sort of inducer (possibly VEGF-B, the positive effect of
which on EA.hy926 cell proliferation was confirmed in arecent study [27], but it is still questionable whether
VEGF-B is produced by MSCs).
The transwell systems are widely used to assess
chemotaxis, which plays an important role during the
early stages of angiogenesis. In our setting, UC-MSCs
secreted chemoattractants for EA.hy926 cells. Similar
results have been reported previously for other cell
lines – HUVEC, human microvascular endothelial cell
line HMEC1, and mouse neural crest-derived cell line
N2a, the effect of UC-MSCs being more pronounced
compared with bone marrow-derived MSCs [26, 28, 29].
Similarly, the UC-MSC-conditioned medium increased
the mobility of EA.hy926 endothelial cells in the mono-
layer scratch experiments; Bronckaers et al. [2] demon-
strate the same effect for bone marrow-derived MSCs.
The “scratch assay” is a common way to analyze prolifer-
ation as combined with directed migration of the cells
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in angiogenesis [31].
UC-MSCs thus secrete factors that may attract endo-
thelial and progenitor cells, while stimulating their mo-
bility; what kind of factors in particular could be partly
deduced from the literature. Interleukin (IL)-8 is shown
to induce cytoskeleton rearrangement and directed mi-
gration of EA.hy926 cells by activation of р38 mitogen-
activated protein kinase signaling [32]. The rate of
migration of endothelial cells in vitro is also shown to
depend on hepatocyte growth factor (HGF) and monocyte
chemoattractant protein-1 (MCP-1) levels in UC-MSC-
conditioned media [28]. These findings are consistent with
other research showing that secretion of IL-8, HGF,
and MCP-1 by UC-MSCs is significantly more intensive
than by MSCs derived from bone marrow or adipose
tissue [13, 20].
Published data on the possibilities of endothelial differ-
entiation of MSCs themselves are rather contradictory.
There exist several protocols that differ in the compos-
ition of inducers (most widely used is VEGF-А-165 at
50 ng/ml), duration of the process of differentiation
(takes from 2 to 28 days), and selection of molecular
markers for the control immunostaining (CD31, von
Willebrand factor (vWF), vascular endothelial cadherin
(VE-cadherin), and VEGFR2 are the most common); ac-
cordingly, the final products of these protocols vary
greatly [33]. At the same time, designating the differenti-
ated MSCs as fully mature and functional endothelial
cells is considered inaccurate; it is therefore more cor-
rect to define these cells as endothelial-like cells [2].
In our experiments, the UC-MSCs were capable of dif-
ferentiation to the CD31+ phenotype under the influence
of differentiation medium containing VEGF-A-165 as an
essential, although insufficient, inducer. In contrast,
Choi et al. [26] observe no expression of endothelial
markers by UC-MSCs after treatment with complex dif-
ferentiation media containing epidermal growth factor
(EGF), VEGF, basic fibroblast growth factor, insulin-like
growth factor-1, hydrocortisone, and some other poten-
tial inducers. In yet another study, UC-MSCs treated
with media containing VEGF, EGF, and hydrocortisone
started to express endothelial markers (vWF, VE-
cadherin, and VEGFR2) uniformly, without any changes
in cell organization or cell morphology [34]. Possibil-
ities of endothelial differentiation of MSCs in vivo are
even more questionable [2]. One of the reasons for this is
the low level of VEGF-A in ischemic tissues: it is about 103
times lower than in standard endothelial differentiation
media (50 ng/ml) [35], and roughly corresponds to the
VEGF-A level in the EA.hy926-conditioned media (Fig. 1d).
The networks formed in coculture of UC-MSCs with
EA.hy926 cells on Matrigel were similar to the net-
works formed by pure UC-MSCs (judging by theirassembly time, length of the tubes, and branching point
number). The core of the mixed networks was com-
posed of the PKH26-labeled MSCs, while the PKH67-
labeled EA.hy926 cells were associated with the outer
surface of this core (Fig 3a). Such an arrangement of
cell types in mixed networks differs from that reported
previously: other authors attribute only a minor role to
MSCs [26, 36, 37]. The inconsistency probably relates
to a different proportion of cell types taken for the net-
work priming.
All tubular networks observed in our setting were un-
stable. Independently of whether they were formed by
UC-MSCs combined with EA.hy926 cells or either of
the cell types on their own, the networks underwent
spontaneous disassembling in the course of 24 hours,
producing tight cell clusters; this is consistent with pre-
viously published data [26, 36, 38]. These clusters,
resulting from 2D network disassembly, subsequently
turned into sprouting centers producing a single stable
3D network. Similar results are reported by Portalska
et al. [38], who observed in vitro assembly of blood
vessel-like structures from bone marrow-derived MSCs
predifferentiated to an endothelial-like phenotype: the
cells started to form a network with a 20-hour delay (as
compared with the native undifferentiated MSCs),
and this network remained stable for at least 7 days.
In pure cultures of endothelial cells, as well in two of
the five mixed cultures, the sprouting occurred in-
variably, but all five pure UC-MSC cultures showed
no signs of the sprouting. This confirms the idea that
individual MSC cultures, equally complying with the
standards, may show morphological and functional
variation [39].
Overall, the results indicate that the ability of UC-
MSCs to participate in sprouting, manifested in cocul-
tures with EA.hy926 cells on Matrigel, is a consequence
of their differentiation to an endothelial-like phenotype
(especially given that the signals from the local environ-
ment, either through cell–cell contact, soluble factors,
or cell–matrix interactions, profoundly influence MSC
endothelial differentiation [37]). We also assume that
the low reproducibility of sprouting indexes between
individual cultures of UC-MSCs is caused mainly by
unequal susceptibility of these cultures to specific
endothelial differentiation stimuli. Notably, acquisition
of the CD31+ phenotype by UC-MSCs in long-term co-
culture with EA.hy926 cells on Matrigel occurred in the
absence of exogenous VEGF-A. It is therefore possible
that the role of VEGF-A in endothelial differentiation
of MSCs is not so significant as believed previously; this
inference is substantiated by the fact that MSCs do not
express membrane-anchored VEGF receptors, although
VEGF-A can signal through platelet-derived growth
factor receptors [40].
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Many of the studies investigating the paracrine factors
secreted from MSCs derived from various sources have
reported the presence of VEGF-A and have implicated
its importance in angiogenesis. In this study, we con-
firmed that MSCs derived from Wharton jelly of the
human umbilical cord produced no detectable quantities
of soluble VEGF-A (VEGF-A-121 and VEGF-A-165);
despite this, culture medium conditioned by UC-MSCs
effectively stimulated the proliferation, motility, and
directed migration of endothelial EA.hy926 cells. These
data suggest that a VEGF-A-independent paracrine
mechanism is involved in the pro-angiogenic activity of
UC-MSCs.
In our experiments, the UC-MSCs were capable of dif-
ferentiation to an endothelial cell-like CD31+ phenotype
under the influence of differentiation medium contain-
ing VEGF-A-165 as an essential, although insufficient,
inducer. However, we found that the ability of UC-MSCs
to participate in secondary sprouting, as manifested in
long-term cocultures with EA.hy926 cells on Matrigel, is
a consequence of their differentiation to an endothelial-
like CD31+ phenotype in the absence of exogenous
VEGF-A. We can assume that signals from the local
environment, either through UC-MSC–EA.hy926 cell
contact or UC-MSC–basement membrane matrix inter-
actions, profoundly influenced UC-MSC differentiation.
Endothelial differentiation as one of the proposed mech-
anisms of action for UC-MSC transplantation can thus
also be partially VEGF-A independent.
The conclusions of this study have practical applications
in the field of pro-angiogenic therapy: VEGF-A-based
therapy supported by an additional VEGF-A-independent
line of intervention (e.g., using UC-MSC transplantation)
may have higher efficacy.
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